Harnessing Immunity to Eliminate Cancer & Chronic Viral Disease
Pinion Immunotherapeutics is a Maryland-based biotechnology company focused on developing novel immunotherapies for chronic viral infections and virus-driven cancers. Its proprietary AI-driven mRNA platform generates immunotherapies targeting HPV-related precancer, AML, EBV, and HSV, designed to activate CD8⁺ T cells while inducing virus-neutralizing antibodies to achieve durable immune control.
AI-Driven Discovery
Proprietary antigen selection optimized for MHC binding, T cell induction, and neutralizing antibody response.
mRNA + LNP Delivery
Engineered LNP for enhanced lymph node trafficking, APC uptake, and superior MHC-I loading vs. protein vaccines.
Dual Immune Activation
Simultaneous induction of CD8⁺ cytotoxic T lymphocytes and virus-neutralizing antibodies for maximum efficacy.
Derisked by Prior Data
Each program supported by prior Phase 1–3 clinical evidence informing antigen selection and proof-of-concept.
WHO WE ARE
Pinion Immunotherapeutics is Built for Capital Efficiency and Scientific Excellence
Pinion operates as a lean, high-impact virtual company, deploying capital directly to science and clinical trials, not overhead. Our leadership team brings deep expertise across mRNA platform development, FDA regulatory strategy, clinical trial design, and immunology.
Our programs target indications with large addressable populations, no curative standard of care, and high economic burden, where mRNA immunotherapy offers a genuine path to functional cure.
5
PIPELINE PROGRAMS
Q2 2026
PHASE I ENROLLMENT
$25M
SERIES A TARGET
OUR PROGRAMS
Development Pipeline
PROGRAM
ARV-2001
HPV-16 PRECANCER
DCAR-001
AML IMMUNOTHERAPY
ARV-1004
EBV THERAPEUTIC
ARV-1003
HBV THERAPEUTIC
PRECLINICAL
IND ENABLING
PHASE I/II TRIAL
Company Address:
Pinion Immunotherapeutics
12358 Parklawn Drive, Suite 230 North Bethesda, MD 20852
Email: klangston@pinionimt.com